



# Biotech Daily

Tuesday March 8, 2022

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: RESONANCE UP 14%**  
- **PROTEOMICS DOWN 12.5%**
- \* **TELIX COMPLETES TLX250-CDX FOR RENAL CANCER IMAGING DOSING**
- \* **CHIMERIC EXTENDS RIGHTS OFFER**
- \* **INCANNEX REQUESTS 'TRIAL RESULTS' TRADING HALT**
- \* **BIO-MELBOURNE AUTOMATES TRIALS, MANAGEMENT**

## MARKET REPORT

The Australian stock market fell 0.83 percent on Tuesday March 8, 2022, with the ASX200 down 58.3 points to 6,980.3 points.

Eleven of the Biotech Daily Top 40 stocks were up, 25 fell and four traded unchanged. All three Big Caps were up.

Yesterday's worst, Resonance, was today's best, up 1.5 cents or 13.6 percent to 12.5 cents, with 305,600 shares traded.

Oncosil climbed 8.6 percent; Amplia was up 7.1 percent; Cynata, Imugene and Mesoblast improved more than four percent; Micro-X was up 3.3 percent; CSL rose 2.8 percent; Clinuvel, Nanosonics, Pro Medicus and Resmed were up more than one percent; with Cochlear and Paradigm up by less than one percent.

Proteomics led the falls, down 14.5 cents or 12.5 percent to \$1.015, with 250,832 shares traded.

Both Compumedics and Uscom lost 9.1 percent; Atomo retreated 8.3 percent; Actinogen and Prescient were down six percent or more; Dimerix and Opthea shed more than five percent; Starpharma fell 4.05 percent; Antisense, Avita, Impedimed and Patrys were down more than three percent; Next Science and Polynovo shed more than two percent; Envision, Medical Developments, Neuren, Orthocell, Pharmaxis and Volpara were down more than one percent; with Cyclopharm, Genetic Signatures, Kazia and Telix down by less than one percent.

## TELIX PHARMACEUTICALS

Telix says it has completed dosing of all 252-patients in its phase III study of TLX250-CDx for the imaging of renal, or kidney, cancer.

Telix said that the zirconium imaging in renal cancer oncology (Zircon) trial was conducted at 34 sites in Europe, Australia, Turkey, Canada and the US.

The company said that TLX250-CDx imaged clear-cell renal cancer with positron emission tomography (PET) and had breakthrough designation from the US Food and Drug Administration.

Telix said that it would continue recruiting for the study for up to an additional three months to generate further data in support of the biologics licence application and provide continued experience for trial sites ahead of its planned transition to a “broader and more accessible expanded access program”.

Telix said that the TLX250-CDx expanded access program was planned to begin in June 2022, with the Zircon results expected by the end of 2022.

Telix chief medical officer, Dr Colin Hayward said the company was “pleased to have reached this important milestone in our phase III program and to have reached target enrolment.”

“Recruitment into this study has accelerated as clinical sites have gradually reopened due to Covid-19 and investigators have become accustomed to using the imaging agent,” Dr Hayward said.

The Atlanta, Georgia-based Emory University School of Medicine’s Dr Viraj Master said that clear cell renal cell carcinoma was “the most common and aggressive form of kidney cancer”.

“There is a clear need for a diagnostic tool that can aid in the management of the disease and better guide surgical decisions,” Dr Master said.

Telix fell two cents or 0.4 percent to \$4.63 with 1.4 million shares traded.

## CHIMERIC THERAPEUTICS

Chimeric says that it has extended the closing day of its retail entitlement offer to raise \$10.7 million at 17 cents a share by seven days, to March 18, 2022.

Chimeric said that the extension was “to ensure all eligible retail shareholders have an additional opportunity to participate in the retail entitlement offer”.

The company said that the extension would have a “consequential effect on the indicative timetable” with the allotment and issue of shares and options expected to be completed on March 25, 2022.

Last month, the company said it had raised \$7.37 million the institutional part of the one-for-3.15, non-renounceable institutional and retail entitlement offer at 17 cents a share which hoped to raise a total of \$18.1 million (BD: Feb 22, 23, 2022).

At that time, Chimeric said that the offer price was an 11.8 percent discount to the theoretical ex-rights price, an 18.3 percent discount to the five-day volume weighted average price and a 15.0 percent discount to the last traded price of its shares.

Chimeric said that the proceeds would “fund payments under ... [its] licence and sponsored research agreements as well as phase I clinical trials” and provide working capital and pay for the costs of the offer.

Chimeric said that one new option would be issued with each new share, exercisable at 25.5 cents by March 31, 2024.

Today, Chimeric said that the expiring date of the new options will remain March 31, 2024.

Chimeric fell half a cent or 3.2 percent to 15 cents.

### [INCANNEX HEALTHCARE](#)

Incannex has requested a trading halt pending an announcement regarding “results of its phase II clinical trial assessing IHL-42X in patients with obstructive sleep apnoea”. Incannex said that trading would resume on March 10, 2022 or on an earlier announcement.

In January, the company said that it had completed dosing patients in a phase II proof-of-concept trial of its marijuana combination product IHL-42X for obstructive sleep apnoea (BD: Jan 16, 2022).

Incannex last traded at 56.5 cents.

### [BIO-MELBOURNE NETWORK](#)

The Bio-Melbourne Network says it will host a symposium on Thursday, titled ‘Automating Document, Trial and Quality Management: Software Application for Healthtech’.

The Network said that Melbourne’s Seerpharma and the Salt Lake City, Utah-based Mastercontrol had assisted more than 50 organizations in the biotechnology sector over the last five years to automate documents, trials and quality management activities.

The Bio-Melbourne Network said that in addition to good manufacturing practice (GMP) compliance, it was recommended that an “effective quality management system is adopted by any health tech organization that intends to commercialize a product”.

“Quality management provides continuous improvement, enhancing patient health outcomes and business success”, the Network said.

The Bio-Melbourne Network said that the event aimed to alleviate the issues and would be hosted by its chief executive officer Jeff Malone, with guest speakers; Mastercontrol director of clinical and regulatory product strategy Patricia Santos-Serrao, Mastercontrol consultant Luana Carone, and Seerpharma contracting services manager Daniel Flewellen.

The Network said that the free virtual event would be held on Thursday, March 10, 2022 from 9am to 10:30am.

For further details and to register, go to: <https://bit.ly/3l4mqtb>.